Table 1

Characteristics of HSCT recipients

Children longitudinal cohortChildren cross-sectional cohortAdults retrospective cohort
Patients (n)406449
Sex, n (%)
 Female17 (42.5)23 (36)18 (36.7)
 Male20 (57.5)41 (64)31 (63.3)
Age, mean years (range)9.4 (0.75–16)7 (0.9–17.8)44.4 (17–65.8)
Primary disease, n (%)
 ALL23 (57.5)25 (39.1)6 (12.2)
 AML11 (27.5)11 (17.2)19 (38.8)
 JMML3 (7.5)2 (3.1)
 NHL1 (2.5)1 (1.6)13 (26.5)
 MDS1 (2.5)2 (3.1)5 (10.2)
 CML1 (2.5)3 (4.7)2 (4.1)
 Others20 (31.2)4 (8.2)
Donor, n (%)
 MSD19 (47.5)32 (50)49 (100%)
 MUD21 (52.5)32 (50)
Stem cell sources, n (%)
 Peripheral blood30 (61.2)
 Bone marrow40 (100)64 (100)19 (38.8)
Conditioning, n (%)
 MA40 (100)64 (100)24 (49)
 NMA25 (51)
 In vivo T-cell depletion, n (%)12 (30)18 (28)20 (40.8)
Acute GVHD
 Grades 1–224 (60)NA
 Grades 3–49 (22.5)NA4 (8.2)
  • ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; CLL, chronic lymphoblastic leukemia; CML, chronic myeloid leukemia; JMML, juvenile myelomonocytic leukemia ; MDS, myelodysplasic syndrome ; MSD, matched sibling donor; MUD, matched unrelated donor; NHL, non-Hodgkin's lymphoma.